New DOJ Guidance on Evaluating Corporate Compliance Programs

Why This Topic Matters

The guidance can help healthcare organizations benchmark their compliance programs against current federal expectations and identify broad areas of risk, oversight, and program performance that may draw scrutiny during an investigation.

Article Sections

1. Overview of the DOJ guidance

   Introduces the updated Department of Justice guidance and explains its purpose in the context of corporate compliance reviews. It also notes the relevance for healthcare organizations.

2. Is the compliance program well-designed?

   Covers the broad factors prosecutors may review when assessing whether a compliance program is structured appropriately. The discussion includes risk assessment, policies and procedures, training, reporting, investigations, and third-party oversight.

3. Is the compliance program effectively implemented?

   Describes the areas used to evaluate whether a program is operating in practice rather than existing only on paper. It includes leadership involvement, board oversight, compliance staffing, incentives, and disciplinary processes.

4. Does the compliance program actually work in practice?

   Summarizes how prosecutors may consider whether a compliance program is functioning as intended over time. The section addresses detection, investigation capacity, remediation, program updates, and testing of improvements.

5. First Healthcare Compliance resource mention

   Briefly references a healthcare compliance software solution and the general categories of compliance support it provides. This material appears as a promotional and attribution-related closing portion of the article.